Zacks Research Issues Pessimistic Forecast for RDY Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Research analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for Dr. Reddy’s Laboratories in a research report issued on Thursday, February 6th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.19 for the quarter, down from their prior forecast of $0.20. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q1 2027 earnings at $0.17 EPS and FY2027 earnings at $0.60 EPS.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%.

Several other research firms also recently commented on RDY. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Finally, Barclays lowered their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th.

Dr. Reddy’s Laboratories Stock Performance

Dr. Reddy’s Laboratories stock opened at $13.82 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The company has a market capitalization of $11.53 billion, a PE ratio of 22.00 and a beta of 0.50. The company has a 50 day moving average price of $14.76 and a 200-day moving average price of $15.34. Dr. Reddy’s Laboratories has a fifty-two week low of $13.36 and a fifty-two week high of $16.89.

Hedge Funds Weigh In On Dr. Reddy’s Laboratories

A number of large investors have recently bought and sold shares of the business. Robeco Institutional Asset Management B.V. increased its holdings in shares of Dr. Reddy’s Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after acquiring an additional 9,373,412 shares during the period. Aikya Investment Management Ltd boosted its position in Dr. Reddy’s Laboratories by 416.1% during the fourth quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company’s stock valued at $88,590,000 after purchasing an additional 4,523,303 shares in the last quarter. Vanguard Group Inc. grew its stake in Dr. Reddy’s Laboratories by 397.2% in the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company’s stock valued at $77,311,000 after purchasing an additional 3,911,404 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Dr. Reddy’s Laboratories by 402.5% in the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company’s stock worth $38,981,000 after purchasing an additional 1,977,419 shares in the last quarter. Finally, GQG Partners LLC lifted its position in shares of Dr. Reddy’s Laboratories by 359.7% during the fourth quarter. GQG Partners LLC now owns 2,008,759 shares of the company’s stock valued at $31,718,000 after buying an additional 1,571,808 shares during the last quarter. Institutional investors own 3.85% of the company’s stock.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.